# An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

> **NCT06938282** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** HRS-4642

## Key facts

- **NCT ID:** NCT06938282
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06938282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06938282, "An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06938282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*